Needham Downgrades Hologic Ahead of COVID-19 Testing Decline

Needham analyst Mike Matson downgraded Hologic to Hold from Buy without a price target.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.